Publications

Found 418 results
2017
Kasturi SPai, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL et al..  2017.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.. J Virol. 91(4)
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med. 23(2):185-191.
Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P.  2017.  Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.. Nat Commun. 8(1):1601.
Lee J H, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, Kong L, Wu NC, McBride R, Sok D, Pauthner M et al..  2017.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.. Immunity. 46(4):690-702.
Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH et al..  2017.  BST-2 Expression Modulates Small CD4 Mimetic Sensitization of HIV-1-infected cells to ADCC.. J Virol. 91(11):pii:e00219-17.
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2017.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng.
Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Wiesch JSchulze Zu, Cubas R, Porichis F, Shalek AK et al..  2017.  Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.. JCI Insight. 2(2):e89574.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373):pii:eaa12144.
Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, Brassard N, Silvestri G, Routy J-P, Havenar-Daughton C et al..  2017.  Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells.. PLoS One. 12(10):e0186998.
Leipold MD, Obermoser G, Fenwick C, Kleinstuber K, Rashidi N, McNevin JP, Nau AN, Wagar LE, Rozot V, Davis MM et al..  2017.  Comparison of CyTOF assays across sites: Results of a six-center pilot study.. J Immunol Methods. :pii:S0022-1759(17)30490-8.
Bale S, Goebrecht G, Stano A, Wilson R, Ota T, Tran K, Ingale J, Zwick MB, Wyatt RT.  2017.  Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.. J Virol. 91(16):pii:e00443-17.
Antunes Rda Silva, Paul S, Sidney J, Weiskopf D, Dan JM, Phillips E, Mallal S, Crotty S, Sette A, Arlehamn CSLindesta.  2017.  Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses.. PLoS One. 12(1):e0169086.
Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens A-J, Ozorowski G et al..  2017.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.. J Exp Med. 214(9):2573-2590.
Haynes BF, Burton DR.  2017.  Developing an HIV vaccine.. Science. 355(6330):1129-1130.
Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ et al..  2017.  Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.. MBio. 8(1):pii:e00036-17.
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature. 543(7646):559-563.
Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su C-Y, Sok D, Khan SN, Garces F et al..  2017.  Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.. Cell Rep. 21(1):222-235.
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA et al..  2017.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.. Immunity. 46(6):1073-1088.e6.
Cirelli KM, Crotty S.  2017.  Germinal center enhancement by extended antigen availability.. Curr Opin Immunol. 47:64-69.
Struwe WB, Stuckmann A, Behrens A-J, Pagel K, Crispin M.  2017.  Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.. ACS Chem Biol. 12(2):357-361.
Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park S-KRobin, Sok D, Su CYao, Delahunty CM, Menis S et al..  2017.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.. Nat Commun. 8:14954.

Pages